

Table 4: Consensus guidelines on the Use of Non-steroidal anti-inflammatory drugs (NSAIDs) (n= 139)				
	Healthy patient	Healthy patient with contact	Sick patient - COVID-19 suspected	Sick patient - COVID-19 positive
To be started	108 (77.7%)	79 (56.8%)	44 (31.7%)	36 (25.9%)
To be maintained	122 (87.8%)	85 (61.2%)	49 (35.3%)	36 (25.9%)
To be decreased	32 (23%)	61 (43.9%)	90 (64.7%)	99 (71.2%)
To be stopped	22 (15.8%)	55 (39.6%)	93 (66.9%)	103 (74.1%)

Consensus for “No”	Consensus for “Yes”
---------------------------	----------------------------

Table 4A: Consensus guidelines on the Use of Non-steroidal anti-inflammatory drugs (NSAIDs) in patients – As per years of experience and uveitis patients per year

	Uveitis specialists' expertise		Healthy patient – without contact	Healthy patient - with contact	Sick patient - COVID-19 suspected	Sick patient - COVID-19 positive
To be started	Years of experience in uveitis	≤ 15 (n = 80)	66 (82.50 %)	51 (63.75 %)	29 (36.25 %)	24 (30.00 %)
		> 15 (n = 59)	42 (71.19 %)	28 (47.46 %)	15 (25.42 %)	12 (20.34 %)
	Uveitis patients on IMT/year	< 300 (n = 85)	66 (77.65 %)	48 (56.47 %)	30 (35.29 %)	23 (27.06 %)
		≥ 300 (n =54)	42 (77.78 %)	31 (57.41 %)	14 (25.93 %)	13 (24.07 %)
To be maintained	Years of experience in uveitis	≤ 15 (n = 80)	72 (90.00 %)	55 (68.75 %)	33 (41.25 %)	24 (30.00 %)
		> 15 (n = 59)	50 (84.75 %)	30 (50.85 %)	16 (27.12 %)	12 (20.34 %)
	Uveitis patients on IMT/year	< 300 (n = 85)	74 (87.06 %)	52 (61.18 %)	31 (36.47 %)	22 (25.88 %)
		≥ 300 (n =54)	48 (88.89 %)	33 (61.11 %)	18 (33.33 %)	14 (25.93 %)
To be decreased	Years of experience in uveitis	≤ 15 (n = 80)	15 (18.75 %)	30 (37.50 %)	50 (62.50 %)	55 (68.75 %)
		> 15 (n = 59)	17 (28.81 %)	31 (52.54 %)	40 (67.80 %)	44 (74.58 %)
	Uveitis patients on IMT/year	< 300 (n = 85)	18 (21.18 %)	35 (41.18 %)	49 (57.65 %)	56 (65.88 %)
		≥ 300 (n =54)	14 (25.93 %)	26 (48.15 %)	41 (75.93 %)	43 (79.63 %)
To be stopped	Years of experience in uveitis	≤ 15 (n = 80)	12 (15.00 %)	26 (32.50 %)	51 (63.75 %)	57 (71.25 %)
		> 15 (n = 59)	10 (16.95 %)	29 (49.15 %)	42 (71.19 %)	46 (77.97 %)
	Uveitis patients on IMT/year	< 300 (n = 85)	11 (12.94 %)	31 (36.47 %)	54 (63.53 %)	61 (71.76 %)
		≥ 300 (n =54)	11 (20.37 %)	24 (44.44 %)	39 (72.22 %)	42 (77.78 %)

Consensus for “No”

Consensus for “Yes”

Table 4B: Consensus guidelines on the Use of Non-steroidal anti-inflammatory drugs (NSAIDs) in patients with Scleritis – As per **geographical region**

	Experts' geographical area	Healthy patient – without contact	Healthy patient - with contact	Sick patient - COVID-19 suspected	Sick patient - COVID-19 positive
To be started	Asia (n = 44)	36 (81.82 %)	24 (54.55 %)	10 (22.73 %)	8 (18.18 %)
	Africa (n = 3)	3 (100.0 %)	1 (33.33 %)	1 (33.33 %)	1 (33.33 %)
	Europe (n = 43)	23 (53.49 %)	18 (41.86 %)	11 (25.58 %)	10 (23.26 %)
	North America (n = 34)	33 (97.06 %)	28 (82.35 %)	16 (47.06 %)	11 (32.35 %)
	South America (n =7)	5 (71.43 %)	1 (14.29 %)	1 (14.29 %)	1 (14.29 %)
	Oceania (n = 8)	8 (100 %)	7 (87.5%)	5 (71.43 %)	5 (71.43 %)
To be maintained	Asia (n = 44)	39 (88.64 %)	23 (52.27 %)	11 (25 %)	8 (18.18 %)
	Africa (n = 3)	3 (100.0 %)	1 (33.33 %)	1 (33.33 %)	1 (33.33 %)
	Europe (n = 43)	33 (76.74 %)	25 (58.14 %)	13 (30.23 %)	10 (23.26 %)
	North America (n = 34)	33 (97.06 %)	28 (82.35 %)	18 (52.94 %)	11 (32.35 %)
	South America (n =7)	6 (85.71 %)	1 (14.29 %)	1 (14.29 %)	1 (14.29 %)
	Oceania (n = 8)	8 (100 %)	7 (87.5 %)	5 (71.43 %)	5 (71.43 %)
To be decreased	Asia (n = 44)	15 (34.09 %)	23 (52.27 %)	33 (75 %)	35 (79.55 %)
	Africa (n = 3)	0	2 (66.67 %)	2 (66.67 %)	2 (66.67 %)
	Europe (n = 43)	13 (30.23 %)	24 (55.81 %)	30 (69.77 %)	32 (74.42 %)
	North America (n = 34)	3 (8.82 %)	6 (17.65 %)	15 (44.12 %)	20 (58.82 %)
	South America (n =7)	1 (14.29 %)	5 (71.43 %)	6 (85.71 %)	6 (85.71 %)
	Oceania (n = 8)	0	1 (14.29 %)	4 (57.14 %)	4 (57.14 %)
To be stopped	Asia (n = 44)	10 (22.73 %)	21 (47.73 %)	32 (72.73 %)	35 (79.55 %)
	Africa (n = 3)	0	1 (33.33 %)	3 (100 %)	3 (100 %)
	Europe (n = 43)	11 (25.58 %)	20 (46.51 %)	32 (74.42 %)	34 (79.07 %)
	North America (n = 34)	0	7 (20.59 %)	16 (47.06 %)	21 (61.76 %)
	South America (n =7)	1 (14.29 %)	5 (71.43 %)	6 (85.71 %)	6 (85.71 %)
	Oceania (n = 8)	0	1 (14.29 %)	4 (57.14 %)	4 (57.14 %)